New study matches melanoma patients to drugs based on their Tumor's genes
NCT ID NCT02645149
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 216 people with advanced melanoma that had stopped responding to standard treatments. Researchers tested each person's tumor for specific genetic changes and then gave them a drug designed to target that change. The goal was to see if this personalized approach could shrink tumors or slow the cancer's growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Targeted drugs (e.g., trametinib, ceritinib, ribociclib, pazopanib) matched to specific genetic mutations in the tumor
What this could lead to
If successful, this approach could offer a new treatment option for people with advanced melanoma whose cancer has stopped responding to standard immunotherapy.
What could go wrong
This is a Phase 2 trial with a small number of participants, so results may not apply to everyone. The targeted drugs may not work for all mutations, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2260, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia